Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient

Alpelisib is a phosphoinositol-3-kinase alpha catalytic subunit (PIK3CA) inhibitor used in patients with PIK3CA mutated breast cancer. The phosphatidylinositol 3-kinase (PI3K) pathway is responsible for activating protein kinase-B (AKT), and activated AKT promotes translation of glucose transporter...

Descripción completa

Detalles Bibliográficos
Autores principales: Fugere, Tyler, Roy, Arya Mariam, Makhoul, Issam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648282/
https://www.ncbi.nlm.nih.gov/pubmed/34900474
http://dx.doi.org/10.7759/cureus.19295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648282/
https://www.ncbi.nlm.nih.gov/pubmed/34900474
http://dx.doi.org/10.7759/cureus.19295

Ejemplares similares